Advertisement
U.S. Markets open in 7 hrs 53 mins

Checkpoint Therapeutics, Inc. (CKPT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.1600-0.0200 (-0.63%)
At close: 04:00PM EDT
3.1499 -0.01 (-0.32%)
After hours: 07:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.1800
Open3.2200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.0800 - 3.2880
52 Week Range1.3600 - 3.6200
Volume933,012
Avg. Volume433,539
Market Cap142.256M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.7100
Earnings DateNov 11, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • GlobeNewswire

    Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

    Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”)

  • GlobeNewswire

    Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

    WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. A webcas